atai Life Sciences (ATAI) Misses Q2 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
atai Life Sciences N.V (ATAI) PT Lowered to $5 at Jefferies
August 13, 2024 4:04 PM EDTJefferies analyst Andrew Tsai lowered the price target on atai Life Sciences N.V (NASDAQ: ATAI) to $5.00 (from $6.00) while maintaining a Buy rating.
The analyst comments "ATAI's pipeline of psychedelics (and non-psychedelics) has pot'l to safely, profoundly, and durably treat tough $1B+... More
